Aramchol Versus Placebo in the Treatment of HIV-associated Nonalcoholic Fatty Liver Disease and Lipodystrophy: A Randomized, Double-blinded, Allocation-concealed, Placebo-controlled Clinical Trial

Trial Profile

Aramchol Versus Placebo in the Treatment of HIV-associated Nonalcoholic Fatty Liver Disease and Lipodystrophy: A Randomized, Double-blinded, Allocation-concealed, Placebo-controlled Clinical Trial

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Mar 2016

At a glance

  • Drugs Aramchol (Primary)
  • Indications Lipodystrophy; Non-alcoholic fatty liver disease
  • Focus Proof of concept; Therapeutic Use
  • Acronyms ARRIVE
  • Most Recent Events

    • 04 Mar 2016 New source identified and integrated. (NCT02684591)
    • 01 Mar 2016 Status changed from not yet recruiting to recruiting, as reported in a ClinicalTrials.gov record.
    • 01 Mar 2016 According to a Galmed Pharmaceuticals media release, first patient has been randomized in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top